SHermansen
TL2 Member · Gdynia, PL
Keeps a personal log and shares the numbers when they are relevant, with the measurement caveats attached.
Joined 9 August 2025 · last posted 5d
85Posts here
3Topics
2Solutions
1.1kLikes received
1.2kLikes given
25Badges
236Days visited
5.3kPosts read
Stated areas
Recent activity
Full stream-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #58 · Compounds › Secretagogues & GH axis · 23 Jul 2026 · 0 likes Worth separating two things that post #54 runs together. IGF-1 as a surrogate: it is a better integrated measure than a spot growth hormone level and it is still a…
-
HbA1c lag and what it can and cannot tell you at eight weeks — one year on Replied, post #19 · Clinical › Bloodwork · 14 Jul 2026 · 6 likes Lipid panel interpretation: total, LDL, HDL, triglycerides all on one panel. Reading them together is more informative than reading one value in isolation. An elevated…
-
An 18-month record including the parts that went badly Replied, post #67 · Outcomes › Progress reports · 12 Jul 2026 · 8 likes Exercise volume changes: increasing exercise intensity or duration can mask weight loss (muscle gain) on the scale. Noting exercise changes when reporting weight helps…
-
What is genuinely unknown about long-term amylin agonism Replied, post #25 · Compounds › Cagrilintide & amylin analogues · 11 Jul 2026 · 1 like Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and…
-
Immortal time bias in a claims-database study — one year on Replied, post #8 · Evidence › Study critique · 5 Jul 2026 · 9 likes Coming back to post #6, because the follow-up matters more than the original answer. What makes a methodological criticism substantive: it identifies a specific feature…
-
Micro-titration: a disputed topic, argued properly Replied, post #87 · Practice › Dosing & titration · 10 Jun 2026 · 6 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Micronutrient adequacy at low total intake Replied, post #14 · Nutrition & Training › Protein & intake · 6 Jun 2026 · 0 likes Timing of protein: spreading protein intake across the day, with some at each meal, is more practical than trying to hit the whole target at one sitting on suppressed…
-
An appeal that succeeded, with the letter structure — the long version Replied, post #41 · Access › Insurance & coverage · 2 Jun 2026 · 2 likes Generic versus brand: most of these compounds do not have generic versions yet. Once they do, formulary coverage and pricing will shift.
-
Reading a trial's population section before its results Replied, post #66 · Evidence › Trials · 29 May 2026 · 1 like Generalisability: the enrolled population was selected in ways that matter. Entry criteria, run-in periods, and the simple fact that people who agree to a multi-year…
-
Revisiting: Primary endpoint hierarchies and why order matters Replied, post #21 · Evidence › Trials · 11 May 2026 · 29 likes The estimand: what the trial set out to estimate. Two trials can be identical in structure but estimate different things by using different handling rules for people…
-
Reimbursement variation across member states Replied, post #5 · Regional › European Union · 2 May 2026 · 16 likes On the opening post — agreed on the reasoning, with one qualification. EMA is the regulator with national implementation. Licensed incretin analogues are…
-
[2026 update] 0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #55 · Devices › Syringes & needles · 23 Apr 2026 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…